Daunorubicin

# daunorubicin ## Overview - **Classification**: Anthracycline Topoisomerase II Inhibitor, Antineoplastic - **Mechanism**: Intercalates into DNA, inhibiting topoisomerase II, leading to DNA strand breaks and inhibition of DNA replication and transcription. ## Primary Indications 1. **Acute Myeloid Leukemia (AML)** - Induction therapy in combination regimens. 2. **Acute Lymphoblastic Leukemia (ALL)** - Induction therapy in combination regimens. ## Adult Dosing ### Standard Dosing **Acute Myeloid Leukemia (AML)** - **Dose**: **45 mg/m²** - **Frequency**: Once daily for 3 days - **Route**: Intravenous (IV) - **Duration**: Initial induction course, often repeated after bone marrow recovery. **Acute Lymphoblastic Leukemia (ALL)** - **Dose**: **25 mg/m²** - **Frequency**: Once daily on days 1, 8, and 15 of treatment cycles - **Route**: Intravenous (IV) ### Dose Adjustments - **Renal Impairment**: CrCl <10 mL/min: Reduce dose by 25-50%. - **Hepatic Impairment**: Bilirubin 1.2-3 mg/dL: Reduce dose by 25-50%. Bilirubin >3 mg/dL: Withhold or significantly reduce dose. - **Elderly Patients**: Monitor closely for increased myelosuppression and cardiotoxicity. May require dose reduction. ## Pediatric Dosing ### Infants (1-12 months) - Use with extreme caution due to increased risk of cardiac toxicity. Not well-established. ### Children (1-12 years) - **Acute Myeloid Leukemia (AML)** - **Dose**: **25-45 mg/m²** - **Frequency**: Once daily for 1-3 days depending on protocol - **Maximum**: **Initial cumulative dose not to exceed 300 mg/m²** for patients who received prior anthracyclines. ### Adolescents (13-18 years) - **Dose**: Generally follows adult dosing guidelines based on body surface area. - **Maximum**: Cumulative lifetime dose should be carefully monitored to minimize cardiac toxicity. ## Safety Information ### Contraindications - **Absolute**: Hypersensitivity to daunorubicin or other anthracyclines. - **Absolute**: Severe myocardial insufficiency or recent myocardial infarction. - **Absolute**: Pre-existing severe and persistent myelosuppression. - **Absolute**: Prior anthracycline cumulative dose limits exceeded. ### Common Adverse Effects - **Very Common (>10%)**: Myelosuppression (neutropenia, thrombocytopenia, anemia), nausea, vomiting, alopecia. - **Common (1-10%)**: Stomatitis, diarrhea, mucositis, localized skin reactions (extravasation). - **Serious but Rare**: Cardiotoxicity (dose-dependent, cumulative), secondary malignancies. ### Key Drug Interactions - **Cardiotoxic Agents**: Increased risk of cardiac toxicity (e.g., trastuzumab, cyclophosphamide). Monitor cardiac function closely. - **Myelosuppressive Agents**: Increased risk of severe myelosuppression. Adjust doses as needed. - **Live/Attenuated Vaccines**: Avoid due to immunosuppression. - **Phenytoin**: Decreased phenytoin levels possible. Monitor and adjust phenytoin. ## Monitoring & Follow-up - **Before Treatment**: Baseline ECG, echocardiogram (LVEF), complete blood count (CBC) with differential, liver/renal function tests, uric acid. - **During Treatment**: Frequent CBCs (daily during induction), LVEF (before each dose or cycle), liver/renal function. - **Clinical Signs**: Monitor for signs of infection (fever), bleeding, cardiac dysfunction (dyspnea, peripheral edema). ## Clinical Pearls - 💡 **Extravasation Risk**: Vesicant; administer via free-flowing IV, monitor injection site. If extravasation occurs, stop infusion, apply ice and consider topical dimethyl sulfoxide (DMSO). - 💡 **Red Urine**: Daunorubicin causes red-orange discoloration of urine, which is expected and harmless. - 💡 **Cardiac Toxicity**: Cumulative lifetime dose is critical, typically **400-550 mg/m²** in adults. Risk increases significantly at higher doses. - 💡 **Pre-medication**: Anti-emetics are generally recommended before administration to mitigate nausea/vomiting. > **⚠️ Important**: This information is for educational purposes only. Always consult current prescribing information, local guidelines, and clinical judgment before prescribing.